Monograph
A10BK01 - Dapagliflozin |
Propably not porphyrinogenic |
PNP |
Side effects
Genital and urinary tract infections are common side effects of dapagliflozin that might potentially be porphyrinogenic.
Rationale
Dapagliflozin is not an inducer or an inhibitor of CYP enzymes and no pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Dapagliflozin is a selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2).
Therapeutic characteristics
Dapagliflozin is an anti-diabetic indicated in adults with type 2 diabetes mellitus to improve glycaemic control. It is administered orally.
Metabolism and pharmacokinetics
Dapagliflozin is bio transformed by UGT1A9 (present in liver and kidney) to dapagliflozin 3-O-glucuronide which is an inactive metabolite. CYP-mediated metabolism is only a minor clearance pathway but involves CYP1A1, 1A2, 2A6, 2C9, 2D6 and 3A4 (Kasichayanula 2014, SPC).
In humans < 10% is metabolized by oxidative metabolism (Maranghi 2015). About 75 % is excreted in the urine and 21 % in the feaces, as metabolites (UpToDate).
In an in vitro study dapagliflozin did not inhibit or induce human P450 enzymes (Obermeier 2010). An in vivo study found that dapagliflozin did not induce or inhibit CYP2C9 or CYP3A4 (Kasichayanula 2012).
Interaction studies indicates that dapagliflozin does not affect the metabolism of CYP 2C9 and CYP 3A4 substrates (Kasichayanula 2014).
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Kasichayanula S, Chang M, et al. Adv Ther. 2012 Feb;29(2):163-77. |
22271159 |
| 2. | Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Kasichayanula S, Liu X, et al. Clin Pharmacokinet. 2014 Jan;53(1):17-27. |
24105299 |
| 3. | Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
Maranghi M, Carnovale A, et al. Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):125-37 |
|
| 4. | In vitro characterization and pharmacokinetics ofdapagliflozin (BMS-512148), a potent sodiumglucose cotransporter type II inhibitor, in animals and humans.
Obermeier M, Yao M et al. Drug Metab Dispos. 2010;38:405-414. |
|
| * | Drug reference publications | |
| 5. | Dapagliflozin: Drug information. Version 186.0. In: UpToDate. (Accessed: 8. December 2016).
|
|
| * | Summary of Product Characteristics | |
| 6. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Forxiga.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Dapagliflozine Aurobindo 10 mg, filmomhulde tabletten · Dapagliflozine Aurobindo 5 mg, filmomhulde tabletten · Dapagliflozine Devatis 10 mg filmomhulde tabletten · Dapagliflozine Devatis 5 mg filmomhulde tabletten · Dapagliflozine HCS 10 mg filmomhulde tabletten · Dapagliflozine HCS 5 mg filmomhulde tabletten · Dapagliflozine Macleods 10 mg filmomhulde tabletten · Dapagliflozine Macleods 5 mg filmomhulde tabletten · Dapagliflozine Viatris 10 mg, filmomhulde tabletten · Dapagliflozine Viatris 5 mg, filmomhulde tabletten · Doxegloze 10 mg, filmomhulde tabletten · Doxegloze 5 mg, filmomhulde tabletten · Edistride 10 mg, filmomhulde tabletten · Edistride 5 mg, filmomhulde tabletten · Forxiga 10 mg, filmomhulde tabletten · Forxiga 5 mg, filmomhulde tabletten 
Dapagliflozin Viatris 10 mg compr. pellic. · Dapagliflozin Viatris 5 mg compr. pellic. · Dapagliflozine HCS 10 mg compr. pellic. · Dapagliflozine HCS 5 mg compr. pellic. · Forxiga 10 mg compr. pellic. · Forxiga 5 mg compr. pellic. 
Dapagliflozina · Dapagliflozina Krka 10 mg Comprimidos Recubiertos con pel?Cula efg · Dapagliflozina Krka 5 mg Comprimidos Recubiertos con pel?Cula efg · Dapagliflozina Macleods 10 mg Comprimidos Recubiertos con Pelicula efg · Dapagliflozina Macleods 5 mg Comprimidos Recubiertos con Pelicula efg · Dapagliflozina Tecnigen 10 mg Comprimidos Recubiertos con Pelicula efg · Dapagliflozina Tecnigen 5 mg Comprimidos Recubiertos con Pelicula efg · Dapagliflozina Teva 10 mg Comprimidos Recubiertos con Pelicula efg · Dapagliflozina Teva 5 mg Comprimidos Recubiertos con Pelicula efg · Dapagliflozina Viatris 10 mg Comprimidos Recubiertos con Pelicula efg · Daperin · Daperin 10 mg Comprimidos Recubiertos con pel?Cula efg · Edistride 10 mg Comprimidos Recubiertos con Pelicula · Edistride 5 mg Comprimidos Recubiertos con Pelicula · Forxiga 10 mg Comprimidos Recubiertos con Pelicula · Forxiga 5 mg Comprimidos Recubiertos con Pelicula · Zedilarf · Zedilarf 10 mg Comprimidos Recubiertos con pel?Cula efg · Zedilarf 5 mg Comprimidos Recubiertos con pel?Cula efg 
Forxiga 
DAFORBIS 10 mg · DAFORBIS 5 mg · DAGETIA 10 mg · DAGETIA 5 mg · DAGRAFORS 10 mg · DAGRAFORS 5 mg · FORXIGA 10 mg · FORXIGA 5 mg 
Forxiga 
Dapagliflozin Devatis · Dapagliflozin Krka · Dapagliflozin Viatris · Edistride · Figozap · Forxiga 
Forxiga 
Daforbis · Dagrafors · Dapagliflozin Viatris · Dapagliflozyna Viatris · Diaflix · Edistride · Forxiga 
Forxiga 10mg · Forxiga 5mg 
Dapagliflozin Krka · Dapagliflozin Krka d.d · Dapaglifozin Adalvo · Dapaglifozin Viatris · Edistride · Forxiga 
Dapagliflozin Devatis · Dapagliflozin Krka · Dapagliflozin ratiopharm · Dapagliflozin Viatris · Edistride · Figozap · Forxiga 
Daglin · Dagrafors · Dapagliflozin Polpharma · Dapagliflozin Viatris · Edistride · Forxiga 
Forxiga®
© NAPOS 2025